皓元医药 (688131.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

41.7x

Market Cap

CNY 19.55B

MomentumView details →

1D Return

−5.88%

YTD Return

—

RSI (14)

45.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

41.7x

Market Cap

CNY 19.55B

RSI (14)

45.9

MomentumView details →

1D Return

−5.88%

YTD Return

—

ProfitabilityView details →

Gross Margin

48.10%

Net Margin

8.18%

EBITDA Margin

15.11%

ROE (TTM)

7.64%

ROA (TTM)

3.78%

Asset Turnover

0.47x

GrowthView details →

Revenue YoY

+26.48%

EPS YoY

−1.21%

FCF YoY

+343.64%

Revenue CAGR 3Y

+28.43%

EPS CAGR 3Y

−5.29%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.47

EPS Surprise

−1.06%

Beats (12Q)

0/12

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

−1.06%

Rev Surprise

−1.06%

Capital & dividendView details →

Debt/Equity

0.45x

Current Ratio

2.16x

Quick Ratio

1.34x

Div Yield

0.26%

Div Rate

CNY 0.23

Div Growth 1Y

−34.78%

Financials snapshotView financials →

Revenue (TTM)

3.00B

Net Income (TTM)

245.26M

Op. CF (TTM)

386.82M

Next earningsOct 29, 2026 →

Latest newsMore news →

Haoyuan Pharmaceutical proposed a cash dividend of 0.90 yuan per 10 shares for the first half of 2026, totaling 19.1911 million yuan, representing 11.21% of net profit attributable to shareholders.9d ago

Similar companies

Viatris Inc.VTRS HUTCHMED (China) Limited00013.HK 哈药股份600664.SH Livzon Pharmaceutical Group Inc.01513.HK Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited00874.HK 天士力600535.SH Find similar companies →

Latest newsMore news →

Haoyuan Pharmaceutical proposed a cash dividend of 0.90 yuan per 10 shares for the first half of 2026, totaling 19.1911 million yuan, representing 11.21% of net profit attributable to shareholders.9d ago